The global pharmaceutical industry experienced a 47% rise in company filings mentions of cybersecurity in Q1 2024 compared with the previous quarter, with the highest share accounted for by GSK with 135% year-on-year increase, according to GlobalData’s analysis of over 669 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q1 2024 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.
Notably, cybersecurity was one of the most frequently referenced themes in Q1 2024, ranking highest in terms of mentions, ahead of digital payments and big data, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, GSK had the greatest increase in references for cybersecurity in Q1 2024, compared with the previous quarter. GlobalData identified 61 cybersecurity-related sentences in the company's filings - 1% of all sentences - and an increase of 135% in Q1 2024 compared with Q1 2023. BioMarin Pharmaceutical’s mentions of cybersecurity rose by 67% to 55 and Legend Biotech’s by 26% to 54 and Amgen’s by 108% to 52 and Alnylam Pharmaceuticals’s by 133% to 49.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for cybersecurity in Q1 2024 was 164.
For further understanding of GlobalData's Pharma: Filings Trends & Signals Q1 2024, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.